Mark Duffett1, Karen Choong2, Jennifer Foster3, Elaine Gilfoyle4, Jacques Lacroix5, Deborah J Cook6. 1. , PhD, RPh, is with the Department of Pediatrics, McMaster University, Hamilton, Ontario. 2. MB, BCh, MSc, is with the Departments of Pediatrics and of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario. 3. , MD, is with the Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia. 4. , MD, MMEd, is with the Department of Paediatrics, University of Calgary, Calgary, Alberta. 5. , MD, is with the Department of Pediatrics, Université de Montréal, Montréal, Quebec. 6. , MD, MSc, is with the Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario.
Abstract
BACKGROUND: Stress ulcer prophylaxis is commonly used in pediatric critical care, to prevent upper gastrointestinal bleeding. The most frequently used agents are histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). The risk-benefit ratio for stress ulcer prophylaxis is uncertain, because data from randomized clinical trials (RCTs) on the effectiveness and harms of prophylaxis in children are limited. OBJECTIVE: To describe the views of Canadian pediatric intensivists about a future RCT of stress ulcer prophylaxis. METHODS: We conducted an online survey of Canadian pediatric critical care physicians. We e-mailed information about the study and a link to a 10-item survey to 111 potential respondents, with 2 reminders for nonrespondents. We assessed the relationship between respondents' characteristics and their views about the need for and potential participation in a trial using logistic regression and assessed regional differences using the χ2 test. RESULTS: The 68 physicians who replied (61% of potential respondents) had a median of 12 (interquartile range 5-20) years of experience. Forty-four (65%) of the respondents stated that a large, rigorous RCT of stress ulcer prophylaxis in children is needed, and 94% (62 of 66) indicated that it should include a placebo group. The 3 most common designs suggested were a 3-arm trial comparing PPI, H2RA, and placebo (56% [37 of 66 respondents to this question]) and 2-arm trials comparing PPI with placebo (15% [n = 10]) and H2RA with placebo (8% [n = 5]). The 5 patient groups that respondents most commonly stated should be excluded (because they should not receive placebo) were children receiving acid suppression at home (66% [42 of 64 respondents to this question]) or corticosteroids (59% [n = 38]), those with severe coagulopathy or receiving extracorporeal membrane oxygenation (both 36% [n = 23]), and those with burns (31% [n = 20]). Most respondents indicated a willingness to participate in an RCT (64% [42 of 66 respondents to this question]), whereas some (29% [n = 19]) indicated that participation would depend on trial design or funding; only 8% (n = 5) were disinclined to participate. CONCLUSIONS: There is considerable interest in a placebo-controlled RCT of stress ulcer prophylaxis among pediatric critical care physicians in Canada, but consensus on key elements of the trial design is needed.
BACKGROUND: Stress ulcer prophylaxis is commonly used in pediatric critical care, to prevent upper gastrointestinal bleeding. The most frequently used agents are histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). The risk-benefit ratio for stress ulcer prophylaxis is uncertain, because data from randomized clinical trials (RCTs) on the effectiveness and harms of prophylaxis in children are limited. OBJECTIVE: To describe the views of Canadian pediatric intensivists about a future RCT of stress ulcer prophylaxis. METHODS: We conducted an online survey of Canadian pediatric critical care physicians. We e-mailed information about the study and a link to a 10-item survey to 111 potential respondents, with 2 reminders for nonrespondents. We assessed the relationship between respondents' characteristics and their views about the need for and potential participation in a trial using logistic regression and assessed regional differences using the χ2 test. RESULTS: The 68 physicians who replied (61% of potential respondents) had a median of 12 (interquartile range 5-20) years of experience. Forty-four (65%) of the respondents stated that a large, rigorous RCT of stress ulcer prophylaxis in children is needed, and 94% (62 of 66) indicated that it should include a placebo group. The 3 most common designs suggested were a 3-arm trial comparing PPI, H2RA, and placebo (56% [37 of 66 respondents to this question]) and 2-arm trials comparing PPI with placebo (15% [n = 10]) and H2RA with placebo (8% [n = 5]). The 5 patient groups that respondents most commonly stated should be excluded (because they should not receive placebo) were children receiving acid suppression at home (66% [42 of 64 respondents to this question]) or corticosteroids (59% [n = 38]), those with severe coagulopathy or receiving extracorporeal membrane oxygenation (both 36% [n = 23]), and those with burns (31% [n = 20]). Most respondents indicated a willingness to participate in an RCT (64% [42 of 66 respondents to this question]), whereas some (29% [n = 19]) indicated that participation would depend on trial design or funding; only 8% (n = 5) were disinclined to participate. CONCLUSIONS: There is considerable interest in a placebo-controlled RCT of stress ulcer prophylaxis among pediatric critical care physicians in Canada, but consensus on key elements of the trial design is needed.
Entities:
Keywords:
essai clinique à répartition aléatoire; pediatric critical care; prophylaxie de l’ulcère de stress; randomized controlled trial; soins intensifs pédiatriques; sondage; stress ulcer prophylaxis; survey
Authors: Mark Duffett; Karen E Burns; Neill K Adhikari; Donald M Arnold; François Lauzier; Michelle E Kho; Maureen O Meade; Omar Hayani; Karen Koo; Karen Choong; François Lamontagne; Qi Zhou; Deborah J Cook Journal: Crit Care Med Date: 2012-02 Impact factor: 7.598
Authors: Melissa Shears; Waleed Alhazzani; John C Marshall; John Muscedere; Richard Hall; Shane W English; Peter M Dodek; François Lauzier; Salmaan Kanji; Mark Duffett; Jeffrey Barletta; Mohammed Alshahrani; Yaseen Arabi; Adam Deane; Deborah J Cook Journal: Can J Anaesth Date: 2016-02-24 Impact factor: 5.063
Authors: Ben D Albert; David Zurakowski; Lori J Bechard; Gregory P Priebe; Christopher P Duggan; Daren K Heyland; Nilesh M Mehta Journal: Pediatr Crit Care Med Date: 2016-10 Impact factor: 3.624